Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Targeting early versions

A 'head start' in the race against pancreatic cancer

Fighting pancreatic cancer can feel like a race against time. A new discovery could give clinicians a head start - by targeting precancerous lesions before they become much more aggressive.

Connect, automate and innovate your lab through SMART Automation 

In today’s fast-paced healthcare landscape, efficiency and accuracy are essential in overcoming workload challenges. Pathology laboratories are under pressure to keep up with growing demands, all…

News • Automated evaluation

Robot enhances side-effect monitoring after cardiac arrhythmia treatment

A newly-developed robot can detect medication side-effects in patients after heart arrhythmia treatment faster than a human doctor, while reducing the number of follow-up tests.